Quick Access

ACVR2A Knockout HEK293 Cell Line

ACVR2A Knockout HEK293 Cell Line

ACVR2A Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.

Cat. No EDC07756
Species Human
Cell Line HEK293
Gene ACVR2A
Size 1×10⁶cells

Product Details

Cat.No. EDC07756 Product Name ACVR2A Knockout HEK293 Cell Line
Cell Line HEK293 Cellosaurus ID CVCL_0045
Cell Line Synonyms Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293 Gene
NCBI Gene ID
92
Gene Synonyms ACTRII|ACVR2
Summary
This gene encodes a receptor that mediates the functions of activins, which are members of the transforming growth factor-beta (TGF-beta) superfamily involved in diverse biological processes. The encoded protein is a transmembrane serine-threonine kinase receptor which mediates signaling by forming heterodimeric complexes with various combinations of type I and type II receptors and ligands in a cell-specific manner. The encoded type II receptor is primarily involved in ligand-binding and includes an extracellular ligand-binding domain, a transmembrane domain and a cytoplasmic serine-threonine kinase domain. This gene may be associated with susceptibility to preeclampsia, a pregnancy-related disease which can result in maternal and fetal morbidity and mortality. Alternative splicing results in multiple transcript variants of this gene. [provided by RefSeq, Jun 2013]
Associated Diseases Non-tumor
Morphology Adherent Passage Ratio 1/5,2days
Complete Culture Medium DMEM + 10% FBS Freezing Medium 95% Complete culture medium+ 5% DMSO
QC Indels validated by Sanger sequencing; sterility confirmed via microbial testing.
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.

STR Profile

LociSTR Info (Sample Cell)
Sample Cell Line: HEK293
STR Info (Cell bank)
Cell Line: HEK293
Allele1Allele2Allele1Allele2
Amelogenin X X
CSF1P0 12 11 12
D2S1338 19 19
D3S1358 15 17 15 17
D5S818 8 8 9
D7S820 11 12 11 12
D8S1179 12 14 12 14
D13S317 12 14 12 14
D16S539 9 13 9 13
D18S51 17 18 17 18
D19S433 15 18 15 18
D21S11 28 30.2 28 30.2
FGA 23 23
Penta D 9 10 9 10
Penta E 7 15 7 15
TH01 7 9.3 7 9.3
TPOX 11 11
vWA 16 19 16 19
D6S1043 11 11
D12S391 19 21 11 15
D2S441 11 15 11 15
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.

FAQ

ACVR2A and ACVR2B are the two type II activin receptors — serine/threonine kinase receptors that bind activins, myostatin (GDF8), GDF11, BMPs, and other TGF-β superfamily ligands; upon ligand binding, the type II receptor recruits and phosphorylates type I receptors (ALK4/ACVR1B, ALK5, ALK7), which then phosphorylate SMAD2/3 (activin/myostatin branch) to regulate gene expression. ACVR2A and ACVR2B share substantial ligand and functional overlap, with myostatin/GDF11-mediated muscle growth suppression being a major shared function. This ligand-trap axis is the basis of several clinically important therapeutics. The choice between knockout and overexpression depends on whether you are studying ACVR2A-specific activin/myostatin signaling. This ACVR2A Knockout in HEK293 is a workhorse mechanistic platform — HEK293 supports systematic structure-function studies of ACVR2A-mediated SMAD2/3 signaling. Overexpression is useful for studying ACVR2A gain-of-function effects. Important consideration: ACVR2A and ACVR2B share substantial ligand binding and functional overlap — single ACVR2A knockout may show modest phenotypes if ACVR2B compensates. This product complements the parallel ACVR2A Knockout in HAP1 and the ACVR2A & ACVR2B Double Knockout in HEK293 (both also available) for systematic paralog dissection. Rescue with wild-type or kinase-dead ACVR2A is the standard specificity control. The knockout is a critical specificity tool for ⭐⭐ sotatercept (Winrevair, FDA-approved 2024 ActRIIA-Fc ligand trap for pulmonary arterial hypertension), luspatercept (Reblozyl, ActRIIB-Fc trap for anemia in MDS/β-thalassemia), bimagrumab (anti-ActRII antibody for muscle/metabolic disease), and emerging activin/myostatin pathway-targeted therapeutics.
Yes. ACVR2A rescue experiments are well-established for activin receptor research: • Construct design: use a codon-modified ACVR2A sequence with a small intracellular C-terminal tag (FLAG, HA). ACVR2A has extracellular ligand-binding domain, single transmembrane span, and intracellular serine/threonine kinase domain — preserve all elements. • Surface localization validation: confirm plasma membrane localization before ligand binding studies. • Kinase-dead rescue: K219R mutation in the ATP-binding lysine abolishes catalytic activity. • Ligand-binding-deficient rescue: extracellular domain mutations disrupt activin/myostatin binding. • Functional readout: rescue should restore activin/myostatin-induced phospho-SMAD2/3 signaling. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
Contact Us
*
*
*
How did you hear about us: